Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)
Technology appraisal
Reference number: TA884
Published:
Following a regulatory update from the company, timelines for this appraisal are to be confirmed. The discussion of this appraisal at the committee meeting in October 2022 has therefore been cancelled. A revised date will be provided in due course.